



MTS13AUSA

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No. : 10/526,111 Confirmation No.: 8522
Applicant : Yousef et al.
Filed : November 22, 2005
TC/A.U. : 1643
Examiner : A. Gussow
Customer No. : 00270 December 22, 2006
Title : METHODS FOR DETECTING ENDOCRINE CANCER

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits to the Examiner the attached document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Copies of the documents listed in these forms are enclosed. This Information Disclosure Statement is submitted more than three months from the filing date of this application, but before receipt of a first Office Action. Therefore, no fees are believed due.

Express Mail No.: EO 928 659 044 US

REMARKS

Listed below are co-pending US patent applications and their corresponding international patent publications.

- (i) US Patent Application No. 11/319,952, filed December 28, 2005
(US Patent Application Publication No. US-2006-0134114,
published June 22, 2006)
- (ii) US Patent Application No. 10/526,029, filed September 20, 2005
(US Patent Application Publication No. US-2006-0073525,
published April 6, 2006)
(International Patent Publication No. WO-2004/021008
published March 11, 2004)
- (iii) US Patent Application No. 10/344,394, filed February 11, 2003
(US Patent Application Publication No. US-2004-0058342,
published March 25, 2004)
(International Patent Publication No. WO-2002/014485,
published February 2, 2002)
- (iv) US Patent Application No. 10/399,013, filed April 10, 2003
(US Patent Application Publication No. US-2004-0096915,
published May 20, 2004)
(International Patent Publication No. WO-2002/035232,
published May 2, 2002)
- (v) US Patent Application No. 10/415,222, filed April 25, 2003
(US Patent Application Publication No. US-2004-0115745,
published June 17, 2004)
(International Patent Publication No. WO-2002/037112,
published May 10, 2002)
- (vi) US Patent Application No. 10/529,163, filed December 19, 2005
(US Patent Application Publication No. US-2006-0223059,
published October 5, 2006)
(International Patent Publication No. WO-2004/029285,
published April 8, 2004)

- (vii) US Patent Application No. 10/529,088, filed March 24, 2005
 (US Patent Application Publication No. US-2006-0269971,
 published November 30, 2006)
 (International Patent Publication No. WO-2004/029616,
 published April 8, 2004)
- (viii) US Patent Application No. 10/868,490, filed June 14, 2004
 (US Patent Application Publication No. US-2005-0106586,
 published May 19, 2005)
- (ix) US Patent Application No. 10/546,435, filed August 19, 2005
 (US Patent Application Publication No. US-2006-0141471,
 published June 29, 2006)
 (International Patent Publication No. WO-2004/077060,
 published September 10, 2004)
- (x) US Patent Application No. 10/544,944, filed August 9, 2005
 (US Patent Application Publication No. US-2006-0134120,
 published June 22, 2006)
 (International Patent Publication No. WO-2004/075713,
 published September 10, 2004)
- (xi) US Patent Application No. 10/510,321, filed October 4, 2004
 (US Patent Application Publication No. US-2005-0287528,
 published December 29, 2005)
 (International Patent Publication No. WO-2003/085404,
 published October 16, 2003)
- (xii) US Patent Application No. 10/492,740, filed April 15, 2004
 (US Patent Application Publication No. US-2005-0176002,
 published August 11, 2005)
 (International Patent Publication No. WO-2003/033731,
 published April 24, 2003)
- (xiii) US Patent Application No. 10/478,333, filed November 21, 2003
 (US Patent Application Publication No. US-2004-0203012,
 published October 14, 2004)
 (International Patent Publication No. WO-2002/097438,
 published December 5, 2002)

The month of publication for documents AAT, AAU, BX, CCV, DY, EU, and EEZ listed on the attached Form 1449 could not be determined. The years of publication for documents AAT, BX, CCV, EU, and EEZ are sufficiently earlier than the effective US filing date and/or the foreign priority date of the present application so that the particular month of publication of the documents is not an issue (MPEP 609).

The Examiner is respectfully requested to consider the documents identified in this paper and in the attached forms during the course of examination of this application.


The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or during the pendency of this application, or credit any overpayment in any fees to our Deposit Account No. 08-3040.

Respectfully submitted,

HOWSON & HOWSON ^{LLP}
Attorneys for Applicants

By: Mary E. Bak
Mary E. Bak
Registration No. 31,215
Suite 210
501 Office Center Drive
Fort Washington, PA 19034
Telephone: 215-540-9200
Telefacsimile: 215-540-5818

December 22, 2006



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/526,111
				Filing Date	November 22, 2005
				First Named Inventor	Yousef et al.
				Art Unit	1643
Examiner Name	A. Gussow				
Sheet	1	of	9	Attorney Docket Number	MTS13AUSA

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA	US-2006-0134114	06-22-2006	Diamandis	
	AB	US-2006-0073525	04-06-2006	Yousef	
	AC	US-2004-0058342	03-25-2004	Yousef et al.	
	AD	US-2004-0096915	05-20-2004	Diamandis	
	AE	US-2006-0223059	10-05-2006	Yousef	
	AF	US-2006-0269971	11-30-2006	Diamandis	
	AG	US-2005-0106586	05-19-2005	Diamandis	
	AH	US-2006-0141471	06-29-2006	Diamandis	
	AI	US-2006-0134120	06-22-2006	Diamandis	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
	AL	WO-2000/053776	09-14-2000	Yousef et al.		
	AM	WO-2002/014485	02-02-2002	Yousef et al.		
	AN	WO-2002/037112	05-10-2002	Diamandis et al.		
	AO	WO-2002/035232	05-02-2002	Diamandis		
	AP	WO-2002/097438	12-05-2002	Diamandis		
	AQ	WO-2003/033731	04-24-2003	Diamandis et al.		
	AAL	WO-2003/085404	10-16-2003	Diamandis et al.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/526,111
				Filing Date	November 22, 2005
				First Named Inventor	Yousef et al.
				Art Unit	1643
				Examiner Name	A. Gussow
Sheet	2	of	9	Attorney Docket Number	MTS13AUSA

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AJ	US-2004-0115745	06-17-2004	Diamandis	
	AK	US-2005-0287528	12-29-2005	Diamandis	
	AAA	US-2005-0176002	08-11-2005	Diamandis	
	AAB	US-2004-0203012	10-14-2004	Diamandis	
	AAC	US-7,022,497	04-04-2006	Yousef et al.	
	AAD	US-6,962,793	11-08-2005	Diamandis	
	AAE	US-2003-0108963	06-12-2003	Schlegel et al.	
	AAF	US-2006-0172608	08-03-2006	Yousef et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ -Kind Code ⁵ (if known)				
	AAM	WO-2004/021008	03-11-2004	Diamandis		
	AAN	WO-2004/029285	04-08-2004	Yousef et al.		
	AAO	WO-2004/029616	04-08-2004	Diamandis		
	AAP	WO-2004/075713	09-10-2004	Diamandis		
	AAQ	WO-2004/077060	09-10-2004	Diamandis et al.		

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known		
				Application Number	10/526,111	
				Filing Date	November 22, 2005	
				First Named Inventor	Yousef et al.	
				Art Unit	1643	
				Examiner Name	A. Gussow	
Sheet	3	of	9	Attorney Docket Number		MTS13AUSA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AR	AIMES et al., "Endothelial Cell Serine Proteases Expressed During Vascular Morphogenesis and Angiogenesis", Throm. Haemost. 89(3):561-572 (March, 2003) (Abstract)	
	AS	AUERSPERG et al., "The Biology of Ovarian Cancer", Semin. Oncol., 25(3):281-304 (June, 1998) (Abstract)	
	AT	BALBAY et al., "Highly Metastatic Human Prostate Cancer Growing within the Prostate of Athymic Mice Overexpresses Vascular Endothelial Growth Factor", Clin. Cancer Res., 5:783-789 (April, 1999)	
	AU	BHOOLA et al., "Bioregulation of Kinins: Kallikreins, Kininogens, and Kininases", Pharm. Rev., 44(1):1-80 (March, 1992)	
	AV	BORGONO et al., "Favorable Prognostic Value of Tissue Human Kallikrein 11 (hK11) in Patients with Ovarian Carcinoma", Int. J. Cancer, 106:605-610 (September 10, 2003)	
	AW	CARDILLO et al., "Androgen Receptors in Ovarian Tumors: Correlation with Oestrogen and Progesterone Receptors in an Immunohistochemical and Semiquantitative Image Analysis Study", J. Exp. Clin. Cancer Res., 18(2):231-237 (June, 1998) (Abstract)	
	AX	CHANG et al., "Identification and Molecular Characterization of Five Novel Kallikrein Gene 13 (KLK13; KLK-L4) Splice Variants: Differential Expression in the Human Testis and Testicular Cancer", Anticancer Res., 21(5):3147-3152 (September-October, 2001) (Abstract)	
	AY	CHEN et al., "Prostasin Serine Protease Inhibits Breast Cancer Invasiveness and is Transcriptionally Regulated by Promoter DNA Methylation", Int. J. Cancer, 97:323-329 (January 20, 2002)	
	AZ	CHEN et al., "Down-Regulation of Prostasin Serine Protease: A Potential Invasion Suppressor in Prostate Cancer", The Prostate, 48:93-103 (July 1, 2001)	
	AAR	CHRISTOPOULOS et al., "Enzymatically Amplified Time-Resolved Fluorescence Immunoassay with Terbium Chelates", Anal. Chem., 64(4): 342 (February 15, 1992)	
	AAS	DAY et al., "Epithelial Carcinoma of the Ovary: Prognostic Importance of Histologic Grade", Natl. Cancer Inst. Monogr. 42:15-21 (October, 1975)	
	AAT	DECLERCK et al., "Proteases and Protease Inhibitors in Tumor Progression", Adv. Exp. Med. Biol., 425:89-97 (1997) (Abstract)	
	AAU	DEL ROSSO et al., "Multiple Pathways of Cell Invasion are Regulated by Multiple Families of Serine Proteases", Clin. & Exp. Metastasis, 19:193-207 (2002)	
	AAV	DEPERTHES et al., "Isolation of Prostatic Kallikrein hK2, Also Known as hGK-1, in Human Seminal Plasma", Biochemica et Biophysica Acta, 1245:311-316 (December 14, 1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/526,111
				Filing Date	November 22, 2005
				First Named Inventor	Yousef et al.
				Art Unit	1643
				Examiner Name	A. Gussow
Sheet	4	of	9	Attorney Docket Number	MTS13AUSA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	AAW	DIAMANDIS et al., "Human Kallikrein 11: A New Biomarker of Prostate and Ovarian Carcinoma", Cancer Res., 62:295-300 (January 1, 2002)	
	AAX	DIAMANDIS et al., "Immunofluorometric assay of Human Kallikrein 6 (Zyme/Protease M/Neurosin) and Preliminary Clinical Applications", Clin. Biochem., 33(5):369-375 (July, 2000)	
	AAY	DIAMANDIS et al., "Human Kallikrein 6 (Zyme/Protease M/Neurosin): A New Serum Biomarker of Ovarian Carcinoma", Clin. Biochem., 33(7):579-583 (October, 2000)	
	AAZ	DIAMANDIS et al., "Human Tissue Kallikreins: A Family of New Cancer Biomarkers", Clin. Chem., 48(8):1198-1205 (August, 2002)	
	BR	DIAMANDIS et al., "New Nomenclature for the Human Tissue Kallikrein Gene Family", Clin. Chem., 46(11):1855 (November 2000)	
	BS	DIAMANDIS et al., "Human Kallikrein 6 (nK6): A New Potential Serum Biomarker for Diagnosis and Prognosis of Ovarian Cancer", J. Clin. Oncol., 21(6):1035-1043 (March 15, 2003)	
	BT	DONG et al., "Human Kallikrein 4 (KLK4) is Highly Expressed in Serous Ovarian Carcinomas", Clin. Cancer Res., 7:2363-2371 (August, 2001)	
	BU	DUFFY, "Proteases as Prognostic Markers in Cancer", Clin. Cancer Res., 2:613-618 (April, 1996)	
	BV	DUFFY, "The Role of Proteolytic Enzymes in Cancer Invasion and Metastasis", Clin. Exp. Metastasis, 10:145-155 (May, 1992)	
	BW	DUFFY et al., "Urokinase Plasminogen Activator: A Prognostic Marker in Multiple Types of Cancer", H. Surg. Oncol., 71:130-135 (June, 1999)	
	BX	EISENHAUER et al., "Ovarian Cancer: Should We Be Managing Patients with Good and Bad Prognostic Factors in the Same Manner", Annals of Oncol., 10(Suppl. 1):S9-S15 (1999)	
	BY	FOEKENS et al., "The Prognostic Value of Polymorphonuclear Leukocyte Elastase in Patients with Primary Breast Cancer", Cancer Res., 63:337-341 (January 15, 2003)	
	BZ	GOTLIEB et al., "Topoisomerase II Immunostaining as a Prognostic Marker for Survival in Ovarian Cancer", Gynecologic Oncology, 82:99-104 (May 31, 2001)	
	BBR	GOYAL et al., "The Role for NES1 Serine Protease as a Novel Tumor Suppressor", Cancer Res., 58:4782-4786 (November 1, 1998)	
	BBS	GRAUER et al., "Identification of Human Glandular Kallikrein hK2 from LNCaP Cells", J. Andrology, 17(4):353 (July/August 1996)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/526,111
				Filing Date	November 22, 2005
				First Named Inventor	Yousef et al.
				Art Unit	1643
Examiner Name	A. Gussow				
Sheet	5	of	9	Attorney Docket Number	MTS13AUSA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	BBT	GRAUER et al., "Detection of Human Glandular Kallikrein, hK2, as Its Precursor Form and in Complex with Protease Inhibitors in Prostate Carcinoma Serum", J. Andrology, 19(4):407-411 (July/August 1998)	
	BBU	HARBECK et al., "Prognostic Impact of Proteolytic Factors (Urokinase-Type Plasminogen Activator, Plasminogen Activator Inhibitor 1, and Cathepsins B, C, and L) in Primary Breast Cancer Reflects Effects of Adjuvant Systemic Therapy", Clin. Cancer Res., 7:2757-2764 (September, 2001)	
	BBV	HATA et al., "Expression of the <i>Endostatin</i> Gene in Epithelial Ovarian Cancer", Clin. Cancer Res., 7:2405-2409 (August, 2001)	
	BBW	HAVIV et al. "DNA Microarrays for Assessing Ovarian Cancer Gene Expression", Mol. Cell., Endocrinol., 191:121-126 (May 31, 2002)	
	BBX	HENDERSON et al., "Hormonal Carcinogenesis", Carcinogenesis, 21(3):427-433 (March, 2000)	
	BBY	HOFFMAN et al., "Immunofluorometric Quantitation and Histochemical Localisation of Kallikrein 6 Protein in Ovarian Cancer Tissue: A New Independent Unfavorable Prognostic Biomarker", Brit. J. Cancer, 87:763-771 (September 23, 2002)	
	BBZ	HOOPER et al., "Identification and Characterization of KLK14, a Novel Kallikrein Serine Protease Gene Located on Human Chromosome 19q13.4 and Expressed in Prostate and Skeletal Muscle", Genomics, 73:117-122 (April 1, 2001)	
	CR	HOOPER et al., "Testisin, a New Human Serine Proteinase Expressed by Premeiotic Testicular Germ Cells and Lost in Testicular Germ Cell Tumors", Cancer Res., 59:3199-3205 (July 1, 1999)	
	CS	HOUGH et al., "Large-Scale Serial Analysis of Gene Expression Reveals Genes Differentially Expressed in Ovarian Cancer", Cancer Res., 60:6281-6287 (November 15, 2000)	
	CT	HSIA et al., "Prognostic Significance of Caspase-3 Expression in Primary Resected Esophageal Squamous Cell Carcinoma", Eur. J. Surg. Oncol., 29:44-48 (February, 2003)	
	CU	IMPOLA et al., "Matrix Metalloproteinase-19 is Expressed by Proliferating Epithelium but Disappears with Neoplastic Dedifferentiation", Int. J. Cancer., 103:709-716 (March 1, 2002)	
	CV	ISOLA, "Immunohistochemical Demonstration of Androgen Receptor in Breast Cancer and its Relationship to Other Prognostic Factors", J. Pathol., 170:31-35 (May, 1993)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/526,111
				Filing Date	November 22, 2005
				First Named Inventor	Yousef et al.
				Art Unit	1643
Examiner Name	A. Gussow				
Sheet	6	of	9	Attorney Docket Number	MTS13AUSA

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	CW	JUNG et al., "Ratio of Free or Complexed Prostate-Specific Antigen (PSA) to Total PSA: Which Ratio Improves Differentiation Between Benign Prostatic Hyperplasia and Prostate Cancer?", Clin. Chem., 46(1):55-62 (January, 2000)	
	CX	KIM et al., "Human Kallikrein Gene 5 (KLK5) Expression is an Indicator of Poor Prognosis in Ovarian Cancer", Br. J. Cancer, 84:643-650 (March 2, 2001)	
	CY	KONECNY et al., "Association of Urokinase-Type Plasminogen Activator and Its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer", Clin. Cancer Res., 7:1743-1749 (June, 2001)	
	CZ	KOS et al., "Cysteine Proteinases and Their Endogenous Inhibitors: Target Proteins for Prognosis, Diagnosis and Therapy in Cancer (Review)", Oncol. Rep., 5:1349-1371 (November-December, 1998) (Abstract)	
	CCR	KYRIAKOPOULOU et al., "Prognostic Value of Quantitatively Assessed KLK7 Expression in Ovarian Cancer", Clin. Biochem., 36:135-143 (March, 2003)	
	CCS	LENGYEL et al., "Expression of Latent Matrix Metalloproteinase 9 (MMP-9) Predicts Survival in Advanced Ovarian Cancer", Gynecol Oncol., 82:291-298 (June 22, 2001)	
	CCT	LIAO et al., "Roles of Androgens in the Development, Growth, and Carcinogenesis of the Mammary Gland", J. Steroid Biochem. Mol. Biol., 80:175-189 (February, 2002)	
	CCU	LILJA et al., "Prostate-Specific Antigen in Serum Occurs Predominantly in Complex with α_1 -Antichymotrypsin", Clin. Chem., 37(9):1618-1625 (September, 1991)	
	CCV	LILJA et al., "Three Predominant Proteins Secreted by the Human Prostate Gland", The Prostate, 12:29-38 (1988)	
	CCW	LUO et al., "The Serum Concentration of Human Kallikrein 10 Represents a Novel Biomarker for Ovarian Cancer Diagnosis and Prognosis", Cancer Res., 63:807-811 (February 15, 2003)	
	CCX	LUO et al., "Prognostic Value of Human Kallikrein 10 Expression in Epithelial Ovarian Carcinoma", Clin. Cancer Res., 7:2372-2379 (August, 2001)	
	CCY	LUO et al., "Immunofluorometric Assay of Human Kallikrein 10 and Its Identification in Biological Fluids and Tissues", Clin. Chem., 46:237-246 (February, 2001)	
	CCZ	LUO et al., "Human Kallikrein 10: A Novel Tumor Marker for Ovarian Carcinoma?", Clin. Chim. Acta., 306:111-118 (April, 2001)	
	DR	MAGKLARA et al., "The Human <i>KLK8</i> (<i>Neuropilin/Ovasin</i>) Gene: Identification of Two Novel Splice Variants and its Prognostic Value in Ovarian Cancer", Clin. Cancer Res., 7:806-811 (April, 2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/526,111
				Filing Date	November 22, 2005
				First Named Inventor	Yousef et al.
				Art Unit	1643
Sheet	7	of	9	Examiner Name	A. Gussow
				Attorney Docket Number	MTS13AUSA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	DS	MASCIULLO et al., "p27 ^{KIP1} Expression Is Associated with Clinical Outcome in Advanced Epithelial Ovarian Cancer: Multivariate Analysis", Clin. Cancer Res., 6:4816-4822 (December, 2000)	
	DT	MCCORMACK et al., "Molecular Forms of Prostate-Specific Antigen and the Human Kallikrein Gene Family: A New Era", Urology, 45(5):729-744 (May, 1995)	
	DU	MIKOLAJCZYK et al., "Prostatic Human Kallikrein 2 Inactivates and Complexes with Plasminogen Activator Inhibitor-1", Int. J. Cancer, 81:439-442 (May 5, 1999)	
	DV	MILDE-LANGOSCH et al., "Expression and Prognostic Value of the Cell-Cycle Regulatory Proteins, Rb, p16 ^{MTS1} , p21 ^{WAF1} , p27 ^{KIP1} , Cyclin E, and Cyclin D2 in Ovarian Cancer", Int. J. Gynecol. Pathol., 22:168-174 (April, 2003)	
	DW	MITSUMI et al., "A Novel Isoform of a Kallikrein-Like Protease, TLSP/Hippostasin, (PRSS20), IS Expressed in the Human Brain and Prostate", Biochem. Biophys. Res. Commun., 272:205-211(May 27, 2000)	
	DX	OBIEZU et al., "Higher Human Kallikrein Gene 4 (KLK4) Expression Indicates Poor Prognosis of Ovarian Cancer Patients", Clin. Cancer Res., 7:2380-2386 (August, 2001)	
	DY	OZALP et al., "Effect of Cellular DNA Content on the Prognosis of Epithelial Ovarian Cancers", Gynecol. Obstet. Invest., 52:93-97 (2001) (Abstract)	
	DZ	PETRAKI et al., "Human Kallikrein 13 Expression in Normal Tissues: An Immunohistochemical Study", Histochem. Cytochem., 51(4):493-501 (April, 2003)	
	DDR	RIEGMAN et al., "Characterization of the Human Kallikrein Locus", Genomics, 14:6-11 (September, 1992)	
	DDS	RISCH, "Hormonal Etiology of Epithelial Ovarian Cancer, With a Hypothesis Concerning the Role of Androgens and Progesterone", J. Natl. Cancer Inst., 90:1774-1786 (December 2, 1998)	
	DDT	ROJO et al., "Expression and Clinical Significance of Pepsinogen C in Epithelial Ovarian Carcinomas", Eur. J. Obstet. Gynecol. Reprod. Biol., 104:58-63 (August 5, 2002) (Abstract)	
	DDU	SAEDI et al., "Human Kallikrein 2 (HK2), But Not Prostate-Specific Antigen (PSA) Rapidly Complexes with Protease Inhibitor 6 (PT-6) Released from Prostate Carcinoma Cells", Int. J. Cancer, 94:558-563 (November, 2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/526,111
				Filing Date	November 22, 2005
				First Named Inventor	Yousef et al.
				Art Unit	1643
Sheet	8	of	9	Examiner Name	A. Gussow
				Attorney Docket Number	MTS13AUSA

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	DDV	SAWIRIS et al., "Development of a Highly Specialized cDNA Array for the Study and Diagnosis of Epithelial Ovarian Cancer", Cancer Res., 62:2923-2928 (May 15, 2002)	
	DDW	SCHMALFELDT et al., Clin. "Increased Expression of a Matrix Metalloproteinases (MMP)-2, MMP-9, the Urokinase-Type Plasminogen Activator is Associated with Progression from Benign to Advanced Ovarian Cancer", Cancer Res., 7:2396-2404 (August, 2001)	
	DDX	SCHUMMER et al., "Comparative Hybridization of an Array of 21,500 Ovarian cDNAs for the Discovery of Genes Overexpressed in Ovarian Carcinomas", Gene, 238:375-389 (October 1, 1999) (Abstract)	
	DDY	SCORILAS, "Immunoenzymatically Determined Pepsinogen C Concentration in Breast Tumor Cytosols: An Independent Favorable Prognostic Factor in Node-Dependent Patients", Clin. Cancer Res. 5:1778-1785 (July, 1999)	
	DDZ	SCORILAS et al., "Human Kallikrein 13 Protein in Ovarian Cancer Cytosols: A New Favorable Prognostic Marker", J. Clin. Oncol., 22(4):678 (February 15, 2004)	
	ER	SEETOO et al., "Quantitative Expression of Protein Markers of Plasminogen Activation System in Prognosis of Colorectal Cancer", J. Surg. Oncol. 82:184-193 (March, 2003)	
	ES	SHEN et al., "Prognostic Significance of Vascular Endothelial Growth Factor Expression in Human Ovarian Carcinoma", Br. J. Cancer, 83:196-203 (July, 2000)	
	ET	SHEVCHENKO et al., "Peptide Sequencing by Mass Spectrometry for Homology Searches and Cloning of Genes", J. Protein Chem., 16(5):481-490 (July, 1997)	
	EU	SOTIROPOULOU et al., "Emerging in the Kallikrein Gene Family for Understanding and Diagnosing Cancer", Oncol. Res. 13(6-10):381-391 (2003) (Abstract)	
	EV	STENMAN et al., "A Complex Between Prostate-Specific Antigen and α 1-Antichymotrypsin is the Major Form of Prostate-Specific Antigen in Serum of Patients with Prostatic Cancer: Assay of the Complex Improves Clinical Sensitivity for Cancer", Cancer Res., 51:222-226 (January 1, 1991)	
	EW	STEPHAN et al., "Molecular Forms of Prostate-Specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer", Cancer Epidemiol. Biomark. Prev., 9:1133-1147 (November, 2000)	
	EX	SUI et al., "Surviving Expression and its Correlation with Cell Proliferation and Prognosis in Epithelial Ovarian Tumors", Int. J. Oncol., 21:315-320 (August, 2002)	
	EY	TAKAHASHI et al., "Down-Regulated Expression of Prostatein in High-Grade or Hormone-Refractory Human Prostate Cancers", The Prostate, 54:187-193 (February 15, 2003)	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet	9	of	9
-------	---	----	---

Application Number	10/526,111
Filing Date	November 22, 2005
First Named Inventor	Yousef et al.
Art Unit	1643
Examiner Name	A. Gussow
Attorney Docket Number	MTS13AUSA

[illegible]

Examiner
Signature

Date
Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313.

If you need assistance in completing the form, call 1-800-PTO-919 and select option 2.